NEW YORK ( TheStreet) -- CHANGE IN RATINGS
were downgraded to neutral at UBS. The company's premium valuation is less warranted given specialty distribution will be less likely to drive superior EPS growth vs. peers, UBS said.
was upgraded at Nomura to neutral from reduce. $6 price target. PRB and Leer ramp warrant neutral rating post selloff, Nomura said.
was downgraded at Mizuho from buy to hold. $18 price target. Recent checks suggest that the company lacks near-term catalysts, Mizuho said.
was initiated with an underperform rating at DA Davidson. $28 price target. Stock is already pricing in a full housing recovery, DA Davidson said.
(BTU - Get Report)
was upgraded at Nomura to neutral from reduce. $22 price target. Cost challenges are well-known, and PRB to inflect higher, Nomura said.
was downgraded to underperform from neutral at Credit Suisse. News that the company will form an MLP will not prove accretive until 2015, Credit Suisse said. Price target is $22.
was upgraded to buy from hold at Jefferies. $56 price target. Hospital industry should benefit from health care reform, Jefferies said.
was upgraded to buy at TheStreet Ratings.
(HLS - Get Report)
was downgraded to neutral at UBS. Also, its price target was reduced to $27. The call is related to the stock's recent run and comes as the government's focus on Medicare payment outlook intensifies, UBS said.
was upgraded at Jefferies to buy. $14.50 price target. Company can continue recent momentum, given health care reform issues, Jefferies said.
(HPQ - Get Report)
was upgraded at Morgan Stanley to overweight. $27 price target. Free cash flow is growing and should exceed net income, Morgan Stanley said.
was upgraded to hold at TheStreet Ratings.
was downgraded at Goldman Sachs to sell from neutral. Company likely will see decelerating growth, Goldman said. $90 price target.
was upgraded at Jefferies to buy. Increased estimates reflect faster, longer methanol peak, Jefferies said. New price target is $54.
(ODP - Get Report)
was upgraded at Keybanc to buy from hold. $4.80 price target. OMX merger will likely have material synergies, Keybanc said.